Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2025 10:00 ET | Source: Derm-Biome Pharmaceuticals, Inc

Derm-Biome’s DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy ageing, is pleased to...
November 25, 2024 10:00 ET | Source: Derm-Biome Pharmaceuticals, Inc

Derm-Biome Pharmaceuticals adds Dr. Jerry Tan, internationally renowned expert in acne and acne scarring, to its Scientific Advisory Board

VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company developing safe and highly effective topical treatments...
October 29, 2024 05:01 ET | Source: Research and Markets

Dermatology Treatment and Care Research Report 2024-2030 with Analyst Recommendations - Tapping into the Demand for Tailored Solutions / Focus on Expansion in Emerging Markets

Dublin, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Dermatology Treatment and Care Market (2024 Edition): Analysis By Treatment Type (Skin Disease and Care, Hair Disease and Care), By Route of...
May 08, 2024 10:00 ET | Source: Derm-Biome Pharmaceuticals, Inc

Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to...
April 16, 2024 16:05 ET | Source: Kamari Pharma

Kamari Pharma Announces Abstracts Accepted for Presentation at the 81st Annual Meeting of the Society for Investigative Dermatology

Late breaking poster presentation includes Phase 1b clinical trial results demonstrating the safety and preliminary efficacy of KM-001, a topical TRPV3 inhibitor, for the treatment of palmoplantar...
February 27, 2024 10:00 ET | Source: Derm-Biome Pharmaceuticals, Inc

Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin...
January 31, 2024 10:47 ET | Source: Research and Markets

Global Crow's Feet Market Analysis Uncovers Growth Trends and Predictions Through 2031

Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Crows Feet Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user,...
January 24, 2024 05:05 ET | Source: Belle.ai

Fighting leprosy with artificial intelligence: DAHW and Belle.ai join forces with Senegal’s Ministry of Health and Social Action to detect and combat neglected diseases

DAHW, Belle.ai and Senegal's Ministry of Health will deploy Belle.ai’s smartphone-based skin AI software to help Senegal eliminate leprosy by 2030.
November 16, 2023 10:53 ET | Source: Research and Markets

Global Dermatology Devices Market Analysis & Forecast to 2023-2033: Increasing Product Approvals by U.S. FDA is Forecast to Boost Market Growth

Dublin, Nov. 16, 2023 (GLOBE NEWSWIRE) -- The "Global Dermatology Devices Market Analysis & Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.The global...
November 16, 2023 07:45 ET | Source: Palvella Therapeutics

Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations

QTORIN™ rapamycin has potential to be first approved therapy and standard of care in the U.S. for Microcystic Lymphatic Malformations Microcystic Lymphatic Malformations is a chronically...

Next Page keyboard_arrow_right